As the influence of a wider range of stakeholders increasingly impacts drug development, what are the best ways to find the right people and start a meaningful dialogue? Andrew Butcher explores this in PharmaPhorum. To read the article, click the link below.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.